TY - JOUR
T1 - Evaluation of adrenaline auto-injector prescription profiles
T2 - A population-based, retrospective cohort study within the National Insurance Claims Database of Japan
AU - Sato, Sakura
AU - Kainuma, Keigo
AU - Noda, Tatsuya
AU - Ebisawa, Motohiro
AU - Futamura, Masaki
AU - Imamura, Tomoaki
AU - Miyagawa, Akihiro
AU - Nakajima, Saeko
AU - Ogawa, Yasushi
AU - Inomata, Takenori
AU - Kan-o, Keiko
AU - Kurashima, Yosuke
AU - Masaki, Katsunori
AU - Myojin, Tomoya
AU - Nishioka, Yuichi
AU - Sakashita, Masafumi
AU - Tamari, Mayumi
AU - Morita, Hideaki
AU - Adachi, Takeya
N1 - Funding Information:
This work was supported in part by grants from the Health and Labor Science Research Grants for Research on Allergic Disease and Immunology administered by the Ministry of Health, Labour and Welfare of Japan ( 201913009A , 21FE2001 ) and Grant-in-Aid for scientific Research (A), Japan Society for the Promotion of Science ( JP18H04126 , JP20H00623 ). The funder had no role in the design, conduct, preparation, or writing of the study manuscript.
Publisher Copyright:
© 2022 Japanese Society of Allergology
PY - 2022/7
Y1 - 2022/7
N2 - Background: Adrenaline is the first-line medication for managing anaphylaxis. A better understanding of prescription trends for adrenaline auto-injectors (AAIs) is important to improving patient care as well as information on health education interventions and medical guidelines. However, it has been difficult to gather comprehensive data in a sustainable manner. Thus, we aimed to investigate trends in AAI prescriptions in Japan. Methods: We searched the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a unique and comprehensive database of health insurance claims, and investigated prescriptions for AAIs for all ages (April 2017 to March 2018). We assessed the annual number of prescriptions per person as well as prescription rates per 100,000 population per year by age, sex, and geographic region. Results: A total of 88,039 subjects (56,109 males, 31,930 female) and 116,758 devices (1.33 AAIs per patient per year) were prescribed AAIs at least once a year for all ages. The prescription rate for AAIs was 69.5 per 100,000 population-years. Patients aged 0–9 years were prescribed AAIs at the rate of 278.9 per 100,000 population-years. Patients aged 0–19 years were 6.4 times more likely to be prescribed AAIs than those over 20 years of age. Males were more frequently prescribed AAIs than females in all age groups, except for those aged 20–24 years. We also evaluated differences in prescription rates by geographic region. Conclusions: This comprehensive evaluation revealed trends in AAI prescriptions, thus helping develop preventive strategies with respect to anaphylaxis in Japan.
AB - Background: Adrenaline is the first-line medication for managing anaphylaxis. A better understanding of prescription trends for adrenaline auto-injectors (AAIs) is important to improving patient care as well as information on health education interventions and medical guidelines. However, it has been difficult to gather comprehensive data in a sustainable manner. Thus, we aimed to investigate trends in AAI prescriptions in Japan. Methods: We searched the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a unique and comprehensive database of health insurance claims, and investigated prescriptions for AAIs for all ages (April 2017 to March 2018). We assessed the annual number of prescriptions per person as well as prescription rates per 100,000 population per year by age, sex, and geographic region. Results: A total of 88,039 subjects (56,109 males, 31,930 female) and 116,758 devices (1.33 AAIs per patient per year) were prescribed AAIs at least once a year for all ages. The prescription rate for AAIs was 69.5 per 100,000 population-years. Patients aged 0–9 years were prescribed AAIs at the rate of 278.9 per 100,000 population-years. Patients aged 0–19 years were 6.4 times more likely to be prescribed AAIs than those over 20 years of age. Males were more frequently prescribed AAIs than females in all age groups, except for those aged 20–24 years. We also evaluated differences in prescription rates by geographic region. Conclusions: This comprehensive evaluation revealed trends in AAI prescriptions, thus helping develop preventive strategies with respect to anaphylaxis in Japan.
KW - Adrenaline
KW - Anaphylaxis
KW - Health insurance
KW - Registry
KW - Self-medication
UR - http://www.scopus.com/inward/record.url?scp=85126695402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126695402&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2022.02.002
DO - 10.1016/j.alit.2022.02.002
M3 - Article
C2 - 35331624
AN - SCOPUS:85126695402
SN - 1323-8930
VL - 71
SP - 354
EP - 361
JO - Allergology International
JF - Allergology International
IS - 3
ER -